Wall Street analyst updates Intel stock price target

Melius reaffirmed a Buy rating on Intel with a $165 price target, implying nearly 70% upside from roughly $97, and argued a sum-of-the-parts valuation could support fair value near $200 per share. Intel reported Q2 revenue of $16.1B, up 25% year over year, and adjusted EPS of $0.42 that beat Wall Street expectations; it also guided Q3 above consensus and increased capital-expenditure plans. The bullish case centers on improving execution, 18A risk production, customer interest in 14A, and foundry expansion, although 2027 capex could exceed 2026 spending by more than $20B and the company issued stock causing about 3.5% dilution.

Analysis

The key valuation debate is not whether Intel can manufacture leading-edge silicon, but whether external customers will commit enough wafer volume to lift fab utilization before the next capital-intensity cycle depresses free cash flow. Foundry economics are highly convex: a modest shortfall in utilization can erase gross-margin gains because depreciation is largely fixed. Customer relationships and preliminary discussions should be discounted until they translate into disclosed multi-year wafer commitments, prepayments, or take-or-pay arrangements.

TSM remains the relevant competitive benchmark, with Intel needing to prove yield, reliability, design-tool readiness and packaging integration—not merely process-node availability. A credible third-party foundry ramp would benefit U.S. semiconductor equipment suppliers and advanced-packaging demand, but could pressure TSM’s strategic scarcity premium only over a 6-18 month horizon. Near term, AI-spending concerns could cap the entire semiconductor complex and obscure company-specific execution progress.

The contrarian risk is that investors capitalize prospective foundry revenue while underweighting the funding requirement and execution lag. Additional capex without external customer prepayments raises the probability of further dilution, incremental leverage, or delayed shareholder returns. The thesis is falsified by a material miss versus manufacturing yield/utilization milestones, weaker gross-margin progression, or a reduction in external-foundry pipeline commentary at the next two earnings reports.

Key Decisions for Investors

• Maintain a tactical long INTC only on pullbacks, sized as a 3-6 month execution trade rather than a structural core holding; target a rerating upon verified external-foundry commitments, with exit discipline if gross margin fails to improve sequentially over two reporting periods.
• Prefer a hedged expression: long INTC / short SOXX or SMH in matched beta for the next 1-3 months. This isolates company-specific manufacturing and customer-conversion upside while reducing exposure to a broad AI-capex de-rating; reassess if semiconductor index weakness exceeds Intel’s relative outperformance by roughly 10 percentage points.
• Do not short TSM solely on Intel’s foundry narrative. Instead, place an alert for disclosed Intel customer prepayments or binding high-volume 18A/14A awards; those events would justify revisiting a long INTC / short TSM relative-value position over 6-12 months.
• Avoid long-dated INTC calls until implied volatility and capex-funded free-cash-flow expectations are reviewed. If options pricing is below realized volatility, use 6-9 month call spreads rather than outright calls, with the upside thesis tied to externally verified customer volume rather than analyst valuation frameworks.